GlassScriptPhysician profile
Chelsea Lyle
NPI 1861033300
$819.11
in general payments reported to CMS, 2019-2025
13 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.06 · 2022: $44.03 · 2023: $90.18 · 2024: $339 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.02 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $204.14 | 2024-2025 | Veozah |
| Mayne Pharma Commercial LLC | $103.39 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $102.67 | 2022-2023 | Imbruvica |
| Abbvie INC. | $89.43 | 2021-2025 | |
| Millicent US INC | $66.07 | 2025 | Intrarosa, Femring, Femlyv |
| Organon LLC | $56.11 | 2024-2025 | Nexplanon |
| Biogen, INC. | $52.63 | 2024 | Zurzuvae |
| Amgen INC. | $30.69 | 2025 | Evenity |
| Exeltis, USA INC. | $30.30 | 2025 | Slynd |
| Ardelyx, INC. | $29.03 | 2025 | Ibsrela |
| Hologic Sales and Service, LLC | $24.90 | 2025 | Myosure Tissue Removal Device, Acessa Provu System |
| Pfizer INC. | $16.18 | 2024 | |
| Daiichi Sankyo INC. | $13.57 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Lyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.